Nuvation Bio Announces Data From Pivotal Phase 2 Trust-I Study of Its Investigational Ros1 Inhibitor, Taletrectinib, Are Published in the Journal of Clinical Oncology and Reported at 2024 Asco Annual Meeting
Nuvation Bio宣佈其在研Ros1抑制劑Taletrectinib的關鍵性2期Trust-I研究的數據已發表在《臨床腫瘤學雜誌》上，並在2024年Asco年會上進行了報道